Snowball logo
logo
CRTX_logo

Cortexyme, Inc

-- $0,00 $  (0%)
Оценка
EPS
-2,963
Рост
Чистый доход, YoY
63,51%
Прогноз
EPS (FWD)
-1,83
Другое
Размер лота
1 шт.
О компании
Тикер
CRTX
ISIN
US22053A1079
Страна
США
Сектор (GICS)
Здравоохранение
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Часто задаваемые вопросы

В каком секторе работает Cortexyme, Inc (CRTX)?

Cortexyme, Inc относится к сектору Здравоохранение.

Выплачивает ли Cortexyme, Inc (CRTX) дивиденды?

Нет, Cortexyme, Inc не выплачивает дивиденды.